However the chart below is quite a telling chart in favour of AZN, although of course the dividend is significantly higher for GSK and that's not factored in to this comparison chart.. |
The share price is certainly heading in the right direction on the chart posted above in post 189, as predicted. |
20 Feb 2025 is the Q4 ex dividend date ..... ;0)) |
“ Note the lawyers (BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP) have filed against multiple companies”
Sort of attempt at corporate genocide then?
:-/ |
Yep, looks like a baseless case brought by some no-win-no-fee cowboys. The company haven't even acknowledged it with a statement which should remain the case |
 The market seemed reasonably pleased with pharmaceutical major GSK (GSK) after the company revealed a better than expected fourth quarter and an upgraded revenue forecast of up to 5 per cent for 2025, with core operating profits growth expected to be 6 to 8 per cent.The company also announced that it is to commence a £2bn share buyback programme that will be completed over the next 18 months. Overall, the results were a welcome tonic after months of steady share price falls. The year seems to have improved significantly as it progressed and GSK produced an operating margin in the fourth quarter of 29 per cent. Strength in its HIV and oncology portfolios was key to the results, offsetting weaknesses in vaccine sales as GSK generated £3bn in free cash flow. Oncology, which is a new area for the company, saw sales almost double at constant currency to £1.41bn.GSK's lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly contributed to the sustained share price fall in the second half of last year.The company noted that while vaccines sales were 4 per cent lower at £9.43bn, immunisation rates have improved year on year for many of its core products such as shingles vaccine Shingrix, sales of which were steady at £3.36bn, but with most of that growth coming outside the US. At just 8.9 times FactSet-compiled consensus forecasts for 2025, GSK is at near-decade lows in PE valuation terms and value investors looking for steady income may well be tempted. Buy. |
Also US shares no stamp duty, FTSE .5% stamp duty, a complete rip off. I think UK shares if they want a proper rating leave London. |
Yes, if action loses, company doesn't lose (shareholders ok). If action wins, shareholders get payout (but impacts their investment) (company loses) |
It does seems like suspicious timing (given the period in question was 2020 to 2022) - I like the Plan though - Wait till the share price spikes, short the hell out of it, then file/announce a weak "Class" claim (on a company scarred by recent litigation), then cash in on the drop (c60p - better than waiting a year for the divi)..
Anyway full claim below if anyone want to lose a few minutes of their life reading it... Note the lawyers (BERNSTEIN LITOWITZ BERGER
& GROSSMANN LLP) have filed against multiple companies... Also note (very last page of the report) the small amount of ADR's their actually talking about - not enough to be worth a claim in itself.. all seems quite suspicious
hxxps://static.blbglaw.com/docs/February%204%2C%202025%20-%20Initial%20Complaint_GSK.pdf |
I think we've got our own share of sickness here with the many claims parasites.
I'm just waiting for the lock stock and two smoking barrels moment, when the claims shysters try to get compensation for their clients, from the timeshare shysters... |
Now Sp falling fast,tighten your seat belts |
Interesting lawsuit. We have had the patients......and now the shareholders. |
Does this mean that we are going back to the times when Zantac was killing the share price to 12 pounds? |
It really is a sick system in the US. |
THE LAWSUIT: A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market "based on information available at the time and correspondence with regulators." GSK also stated that it was "continuing with investigations into the potential source of NDMA." Defendants also assured investors that "GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," findings that were "consistent with other ranitidine data published prior to 2019." Finally, defendants claimed that they could not "quantify or reliably estimate the liability." These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market. WHAT'S NEXT? If you suffered a loss in GSK stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=127930&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate. |
At risk of being seen to be behind the curve...Is there a new class action lawsuit?! ? |
Bought shares that went down? Not your fault as clearly someone else is to blame as shares should only go up in a nice linear fashion. Call 0800-SOBSTORY and we'll chase the crooks for you.
As above I've seen this sort of guff multiple times. It would be very hard to prove, I'd be surprised if it ever got off the ground and I doubt it would amount to much in any case.
Notable AZN also down today, may be something sector specific |
EI those sort of actions are common in the US and usually come to nothing. I have held several US stocks that have been targeted like that. |
It's also investing billions in US factories and employs 1000's there |
Gsk is like an orphan easy to pick-on and manipulate as suggested by the hedgehogs their paymasters mainly the yanks. |
Why should it deter anyone when the company is consistently upgrading forcasts and is one of the if not the lowest valued big name Pharma on world stock markets? |
Mark, does the US class action not deter you.
Given this is a British business and we know how US corts tend to punish non American companies. |
just added some more gsk this morning.Buy and hold especially after the latest update |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
